A Lipid Micellar System Loaded with Dexamethasone Palmitate Alleviates Rheumatoid Arthritis

Wang, Xinxin; Feng, Ye; Fu, Jijun; Wu, Cuishuan; He, Bing; Zhang, Hua; Wang, Xueqing; Dai, Wenbing; Sun, Yong; Zhang, Qiang

doi:10.1208/s12249-019-1449-1

Cited by 12 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Copolymeric micelles loaded with indomethacin, a non-steroidal anti-inflammatory drug that can effectively control inflammation [66], have been found to significantly relieve inflammatory symptoms and decrease the arthritic index and paw diameter in AIA rats. Similarly, micelles loaded with dexamethasone palmitate have been found to accumulate at inflamed sites and to decrease joint inflammation [67]. In another study, maltodextrin-α-tocopherol nano-micelles loaded with tacrolimus (TAC@MD-α-TOC) have been prepared for RA therapy.…”

Section: Polymeric Micellesmentioning

confidence: 99%

Recent advances in nano-targeting drug delivery systems for rheumatoid arthritis treatment

Gou

Liao

et al. 2023

Acta Materia Medica

View full text Add to dashboard Cite

Rheumatoid arthritis is a systemic inflammatory disease that can lead to articular cartilage destruction and periarticular bone erosion, thus ultimately compromising joint integrity and function. Anti-inflammatory drugs and biological agents are commonly used to treat rheumatoid arthritis, but they cannot selectively target inflamed joints, because of their systemic mechanisms, short half-lives and low bioavailability. Consequently, these agents must be used at high doses and delivered frequently, thereby increasing costs and the risk of adverse effects. Drug delivery systems, such as nanoparticles, liposomes and micelles, can significantly prolong drug half-life in the body and enable targeted delivery into the joints. In this review, we comprehensively describe the pathogenesis and clinical diagnosis of rheumatoid arthritis, and summarize recent advances in targeted therapeutic strategies, particularly nano-targeting systems for rheumatoid arthritis.

show abstract

Section: Polymeric Micellesmentioning

confidence: 99%

Recent advances in nano-targeting drug delivery systems for rheumatoid arthritis treatment

Gou

Liao

et al. 2023

Acta Materia Medica

View full text Add to dashboard Cite

show abstract

“…However, its usage is limited due to poor water solubility, tissue distribution, and in vivo bioavailability. To overcome these limitations, researchers have developed DEX palmitate-loaded lipid-based mixed micelles containing sodium glycocholate/egg yolk lecithin for the treatment of RA with effectiveness . In summary, LNPs such as SLNs, liposomes, and niosomes, comprised of DEX, provide excellent benefits in treating various diseases and may have the potential to develop future clinical treatment options …”

Section: Dexamethasone Delivery Systemsmentioning

confidence: 99%

Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems

Madamsetty

Mohammadinejad

Uzielienè

et al. 2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Dexamethasone (DEX) has been widely used to treat a variety of diseases, including autoimmune diseases, allergies, ocular disorders, cancer, and, more recently, COVID-19. However, DEX usage is often restricted in the clinic due to its poor water solubility. When administered through a systemic route, it can elicit severe side effects, such as hypertension, peptic ulcers, hyperglycemia, and hydro-electrolytic disorders. There is currently much interest in developing efficient DEX-loaded nanoformulations that ameliorate adverse disease effects inhibiting advancements in scientific research. Various nanoparticles have been developed to selectively deliver drugs without destroying healthy cells or organs in recent years. In the present review, we have summarized some of the most attractive applications of DEX-loaded delivery systems, including liposomes, polymers, hydrogels, nanofibers, silica, calcium phosphate, and hydroxyapatite. This review provides our readers with a broad spectrum of nanomedicine approaches to deliver DEX safely.

show abstract

“…Dex can suppress RA inflammatory consequences by inhibiting macrophage accumulation, reducing capillary permeability and eventually joint swelling and inflammation are alleviated. 6,7 Prolonged treatment period with GCs can be associated with numerous undesirable side effects such as high blood sugar level, osteoporosis, infection, hyperglycemia and increased risk of cardiovascular diseases like myocardial infarction, stroke, adrenal insufficiency, immune suppression and hypertension. 4,8,9 NSAIDs and GCs are used as first-line treatment medications for relief.…”

Section: Introductionmentioning

confidence: 99%

Intra-Articular Dual Drug Delivery for Synergistic Rheumatoid Arthritis Treatment

Zewail

Nafee

Boraie

2021

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

A Lipid Micellar System Loaded with Dexamethasone Palmitate Alleviates Rheumatoid Arthritis

Cited by 12 publications

References 42 publications

Recent advances in nano-targeting drug delivery systems for rheumatoid arthritis treatment

Recent advances in nano-targeting drug delivery systems for rheumatoid arthritis treatment

Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems

Intra-Articular Dual Drug Delivery for Synergistic Rheumatoid Arthritis Treatment

Contact Info

Product

Resources

About